Purchase this article with an account.
J. Diaz-Rubio, Sr., V. Kon, M. Torres, G. Garcia, M. Gordon, D. Ochoa, V. Morales, J. Guerrero, J. Fromow, H. Quiroz-Mercado; Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5752.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Comparison between Oxane HD and Densiron in complicated cases of inferior rhegmatogenous retinal re-detachment has never been reported. Our purpose was to compare the safety, intraocular adverse effects and anatomic and functional outcome with two endotamponade silicone oil after 3 months in inferior retinal re-detachment with proliferative vitreoretinopathy (PVR).
Fifteen eyes of 15 patients aged 18-65 (mean 44 years) with retinal re-detachment due to inferior PVR (stage ≥C2) were included. Oxane HD was used in thirteen eyes, and Densiron in two. Heavy silicone oil was injected at the end of vitrectomy. Follow-up examinations were scheduled at 1 and 3 months.
There were no significant differences between both groups at the beginning of the study. Ten eyes (76.9%) with Oxane HD and one eye (50%) with Densiron showed macular attachment at the last follow-up. Mean follow-up was 82.7±15.9 days. Visual acuity with Oxane improved in 5 eyes (38.5%), was stable in 5 eyes (38.5%) and worsened in 3 eyes (23.1%). Visual acuity with Densiron improved in 1 eye and worsened in 1 eye (not statistically significant). Five eyes treated with Oxane developed complications (38.5%): temporary inflammatory reaction and fibrin accumulation (n=1), vitreous hemorrhage (n=1), elevated IOP (n=1), emulsification (n=1) and hypotony (n=1). One eye treated with Densiron had elevated IOP.
The anatomical success rate was 76.9% with Oxane HD and 50% with Densiron. We did not observe significant difference between the two endotamponades in relation to anatomic and functional outcome. The results of this prospective study show intraocular tolerante of heavy silicone oils in the two groups for at least 3 months without significant side effects.
This PDF is available to Subscribers Only